Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIALE-T maintenance venetoclax + azacitidine after allogeneic stem cell transplantation in AML
2019-002621-30Phase 2Unknown
- Sponsor
- AbbVie Inc.
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of venetoclax and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Dose-limiting toxicities (DLTs) of venetoclax + azacitidine (Part I). Status: unknown.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2019-002621-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002621-30.